{
  "nctId": "NCT04577651",
  "briefTitle": "Cartesia eXTend 3D Study",
  "officialTitle": "Study to Evaluate Boston Scientific Vercise Cartesia 16-contact Directional Lead (X/HX) With Deep Brain Stimulation (DBS) Systems for the Treatment of Parkinson's Disease (PD)",
  "protocolDocument": {
    "nctId": "NCT04577651",
    "filename": "Prot_SAP_001.pdf",
    "label": "Study Protocol and Statistical Analysis Plan",
    "date": "2021-04-15",
    "uploadDate": "2024-03-27T16:57",
    "size": 25364697,
    "downloadUrl": "https://clinicaltrials.gov/api/v2/studies/NCT04577651/document/Prot_SAP_001.pdf",
    "hasProtocol": true,
    "hasSap": true,
    "hasIcf": false
  },
  "phase": [
    "NA"
  ],
  "studyType": "INTERVENTIONAL",
  "allocation": "NA",
  "interventionModel": "SINGLE_GROUP",
  "masking": "NONE",
  "enrollmentInfo": {
    "enrollmentCount": 58,
    "enrollmentType": "ACTUAL"
  },
  "timeline": {
    "startDate": "2020-11-02",
    "completionDate": "2025-01-28",
    "primaryCompletionDate": "2023-02-27",
    "firstSubmitDate": "2020-09-26",
    "firstPostDate": "2020-10-08"
  },
  "eligibilityCriteria": {
    "criteria": "Key Inclusion Criteria:\n\n* Candidate for DBS implant in the treatment of Parkinson's disease\n* Must be on stable anti-parkinsonian medications for 28 days prior to Informed Consent\n* Persistent disabling Parkinson's disease symptoms such as dyskinesias, motor fluctuations, or disabling \"off\" periods despite optimal medical therapy\n* Be willing and able to comply with all visits and study related procedures (e.g., using the remote control, charging system, etc.).\n\nKey Exclusion Criteria:\n\n* Any intracranial abnormality or medical condition that would contraindicate DBS surgery\n* Have any significant psychiatric or cognitive condition likely to compromise the subject's ability to comply with requirements of the study protocol (e.g. bipolar, schizophrenia, mood disorder with psychotic features, cluster B personality disorders)\n* Any current drug or alcohol abuse, as determined by the investigator\n* Any history of recurrent or unprovoked seizures",
    "healthyVolunteers": false,
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": [
      "ADULT",
      "OLDER_ADULT"
    ]
  },
  "endpoints": {
    "primary": [
      {
        "measure": "Change in Motor Function",
        "description": "Mean change in Movement Disorder Society-Sponsored Revision of the Unified Parkinson's Disease Rating (MDS-UPDRS) Part III scores from Baseline in meds off condition to 12 weeks post device-activation in stim on/meds off condition. Range 0 - 108. Higher scores indicate worse function.",
        "timeFrame": "12 weeks post device-activation"
      }
    ],
    "secondary": [
      {
        "measure": "Change in Motor Function",
        "description": "Mean change in Movement Disorder Society-Sponsored Revision of the Unified Parkinson's Disease Rating (MDS-UPDRS) Part III scores from Baseline (meds off) to 26 weeks post device-activation (stim on/meds off). Range 0 - 108. Higher scores indicate worse function.",
        "timeFrame": "26 weeks post device-activation"
      },
      {
        "measure": "Change in Motor Function",
        "description": "Mean change in Movement Disorder Society-Sponsored Revision of the Unified Parkinson's Disease Rating (MDS-UPDRS) Part III scores from Baseline (meds off) to 52 weeks post device-activation (stim on/meds off). Range 0 - 108. Higher scores indicate worse function.",
        "timeFrame": "52 weeks post device-activation"
      },
      {
        "measure": "Change in Quality of Life",
        "description": "Mean change in Parkinson's Disease Questionnaire (PDQ-39) summary scores from Baseline (meds on) to 12 weeks post device-activation (stim on/meds on). Scores range from 0 to 100, with 0 representing perfect health and 100 representing worst health.",
        "timeFrame": "12 weeks post device-activation"
      },
      {
        "measure": "Change in Quality of Life",
        "description": "Mean change in Parkinson's Disease Questionnaire (PDQ-39) summary scores from Baseline (meds on) to 26 weeks post device-activation (stim on/meds on). Scores range from 0 to 100, with 0 representing perfect health and 100 representing worst health.",
        "timeFrame": "26 weeks post device-activation"
      },
      {
        "measure": "Change in Quality of Life",
        "description": "Mean change in Parkinson's Disease Questionnaire (PDQ-39) summary scores from Baseline (meds on) to 52 weeks post device-activation (stim on/meds on). Scores range from 0 to 100, with 0 representing perfect health and 100 representing worst health.",
        "timeFrame": "52 weeks post device-activation"
      }
    ],
    "other": []
  },
  "complexityMetrics": {
    "eligibilityCriteria": {
      "inclusionCount": 1,
      "exclusionCount": 1,
      "totalCount": 2
    },
    "endpoints": {
      "primaryCount": 1,
      "secondaryCount": 5,
      "otherCount": 0,
      "totalCount": 6
    },
    "studyDesign": {
      "phases": [
        "NA"
      ],
      "isRandomized": false,
      "isMasked": false,
      "interventionModel": "SINGLE_GROUP"
    },
    "overallComplexityScore": 39,
    "complexityCategory": "Moderate"
  },
  "collectionDate": "2025-09-22T02:29:43.640Z",
  "dataSource": "ClinicalTrials.gov API v2 - Comprehensive Collection"
}